CD274 and ischemic stroke: This study aims to evaluate the therapeutic efficacy of programmed death‐ligand 1 (PD‐L1) monoclonal antibody (mAb) in modulating immune responses and neurovascular repair following ischemic stroke, with a focus on age‐dependent differences.